Spikes have been reported in Covid-19 cases in India, as several variants have been found, leading to fears of another wave.

The health ministry has not correlated this in recent cases, but these types have been found mainly in states like Punjab and Maharashtra, two states that the health ministry has called “serious concerns”, they are contributing. The burden of most cases in the country.

Gularia said the emergence of more contagious infections in the UK in some states could be one of the factors contributing to the recent increase in the number of cases.

“Such a change promotes immunity and increases infection,” the health ministry said. He further added that further analysis is being done.

But since early March, it has become clear that cases are slowly rising again – and have erupted in the last few weeks.

India now has a total of more than 11.7 million cases and 160,000 related deaths, according to Johns Hopkins University.

The second wave is “something we’ve already seen in many European countries; we’re following them,” Guleria said.

Guleria explained that a number of factors are contributing to that increase.

He said, ‘One factor is that it’s been a year today since India went down lockdown and there are people who feel cowardly tired,’ he added, ‘You’ve seen that in the community, when you go out, wearing A mask has become less and less.

He added, “We see that in India crowds develop, parties are held, many wedding ceremonies take place.”

Variables and change

All viruses evolve over time, and sometimes mutate when they replicate. Some mutations have little effect – but others can make the variable more easily transmissible, or cause an infection with more severe symptoms.

Of the nearly 10,787 samples analyzed in 18 states on genomics by the Indian SARS-CV-2 consortium, 771 cases of various types of anxiety were found, most of which were from the UK, according to the Ministry of Health. Thirty squares were the first known variant in South Africa and one Brazilian variant was P.1.

The Ministry of Health and Family Welfare also said it has found a type of change that does not match previously identified types of anxiety.

It is not uncommon to see multiple changes in one type. “All of these viruses (variants) that we are dealing with are already mutants,” said virologist T Jacob Joan. He added that the tensions that were becoming prevalent globally were already different from the first tensions that began in Wuhan, he added.

How dangerous the change is depends on where the virus is going. For example, there is a change in the South African variant that changes the composition of the spike protein, which appears to affect the receptor binding domain – the part of the spike protein that is most important for attaching and infecting cells. Researchers are now investigating whether it could help the virus escape partially from the effects of the vaccine.

Guleria warned that the new variant is not necessarily the cause of the alarm, as researchers are still investigating the impact of the change.

“They are not clear on the significance of this,” he said. “Does it have clinical significance or is it just an observation? And it has to be linked to the epidemiological data that is happening.”

One question is what types – and what mutations – can avoid the effects of our existing vaccines.

“If someone was infected with the coronavirus six months ago, that person is free of the non-mutated coronavirus.” Said John. “But is that person still immune to variables? (Should be studied) studied.”

India’s vaccination drive

Meanwhile, Indian authorities are working to control the spike by imposing new sanctions and advancing the country’s vaccination program.

India is administering two vaccines locally. A Covishield is a vaccine developed by Oxford University and AstraZeneca and produced by the Serum Institute of India, the world’s largest vaccine manufacturer. The second is India’s first coronavirus vaccine, covacin, jointly developed by India Biotech and the government-run Indian Medical Research Council.

Serum Institute India f India not only produces most of the vaccines for India – it is also responsible for vaccines distributed in the rest of the world. In September last year, SII promised to produce and deliver 200 million doses of COVAX – a WHO vaccine combination designed to ensure fair access to vaccines.

But SII has had to halt or delay its exports several times in recent months due to rising global and domestic demand.

On January 4, India banned the export of AstraZeneca vaccine manufactured by SII until at least March. SII CEO Adar Poonawala said at the time, “We were given a restricted license only to give it and provide it to the Government of India because they want to give priority to the most vulnerable and needy class.” “The only condition is that we can only supply it to the Government of India, we cannot sell it in the private market, and we cannot export it.”

On Thursday, Reuters reported that India would delay the delivery of the AstraZeneca vaccine to Costrax, citing UNICEF. According to Reuters, India had a temporary hold on all major exports of AstraZeneca shots made by SII.

CNN SII, UNICEF and the Ministry of External Affairs have reached out for comment, but have not yet received a response.

The home ministry also unveiled new infection control guidelines on Tuesday, which will run until the end of April. Some measures include quickly separating positive cases and finding their contacts within 72 hours.

Several cities and states, including Mumbai, Delhi and Odisha, have banned gatherings during the upcoming festival of colors, Holi, on March 28.